ALNYLAM PHARMACEUTICALS, INC. Debt Instrument, Interest Rate, Stated Percentage
ALNYLAM PHARMACEUTICALS, INC. (ALNY) had Debt Instrument, Interest Rate, Stated Percentage of 10.00% as of 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Notes
us-gaap:DebtInstrumentInterestRateStatedPercentage · last filed 2026-02-12
- 2025-12-31: Debt Instrument, Interest Rate, Stated Percentage 10.00%.
- 2025-09-30: Debt Instrument, Interest Rate, Stated Percentage 10.00%.
- 2025-06-30: Debt Instrument, Interest Rate, Stated Percentage 10.00%.
- 2025-03-31: Debt Instrument, Interest Rate, Stated Percentage 10.00%.
| Period end | Debt Instrument, Interest Rate, Stated Percentage | Debt Instrument, Interest Rate, Stated Percentage as first filed |
|---|---|---|
| 2025-12-31 | 10.00% 10-K · filed 2026-02-12 | |
| 2025-09-30 | 10.00% 10-Q · filed 2025-10-30 | |
| 2025-06-30 | 10.00% 10-Q · filed 2025-07-31 | |
| 2025-03-31 | 10.00% 10-Q · filed 2025-05-01 | |
| 2024-12-31 | 10.00% 10-K · filed 2025-02-13 | |
| 2024-09-30 | 11.00% 10-Q · filed 2024-10-31 | |
| 2024-06-30 | 11.00% 10-Q · filed 2024-08-01 | |
| 2024-03-31 | 11.00% 10-Q · filed 2024-05-02 | |
| 2023-12-31 | 11.00% 10-K · filed 2024-02-15 | |
| 2023-09-30 | 12.00% 10-Q · filed 2023-11-02 | |
| 2023-06-30 | 12.00% 10-Q · filed 2023-08-03 | |
| 2023-03-31 | 12.00% 10-Q · filed 2023-05-04 | |
| 2022-12-31 | 12.00% 10-K · filed 2023-02-23 | |
| 2022-09-30 | 13.00% 10-Q · filed 2022-10-27 | |
| 2022-06-30 | 13.00% 10-Q · filed 2022-07-28 | |
| 2022-03-31 | 14.00% 10-Q · filed 2022-04-28 | |
| 2021-09-30 | 15.00% 10-Q · filed 2021-10-28 | |
| 2021-06-30 | 15.00% 10-Q · filed 2021-08-03 | |
| 2021-03-31 | 15.00% 10-Q · filed 2021-04-29 | |
| 2020-08-31 | 14.00% 10-K · filed 2022-02-10 | 17.00% 10-Q · filed 2020-11-05 |
| 2020-08-15 | 15.00% 10-K · filed 2021-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |